Mika Kontro

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients.

Journal: British journal of haematology
Published: March 05, 2026

TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

Journal: Cancer immunology research
Published: February 04, 2026

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML.

Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML.

Journal: Cell stem cell
Published: October 09, 2025

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.

Journal: Journal of internal medicine
Published: August 08, 2025

Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations.

Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 08, 2025

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Journal: HemaSphere
Published: June 24, 2025

Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia.

Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia.

Journal: Molecular oncology
Published: February 06, 2025

Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.

Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 trial.

Journal: The Lancet. Haematology
Published: December 15, 2024

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.

Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial.

Journal: Basic & clinical pharmacology & toxicology
Published: November 18, 2024

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.

CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies.

Journal: Scientific reports
Published: November 16, 2024

Estimating the use of biological samples in Finnish biobanks and hospital collections.

Estimating the use of biological samples in Finnish biobanks and hospital collections.

Journal: European journal of human genetics : EJHG
Published: October 24, 2024

A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

Journal: Cancer research
Published: October 15, 2024
Showing 1-12 of 54

Last Updated: 09/26/2026